Drug
mFOLFOX 6
mFOLFOX 6 is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(25%)
Results Posted
100%(1 trials)
Phase Distribution
Ph phase_2
2
50%
Ph phase_3
2
50%
Phase Distribution
0
Early Stage
2
Mid Stage
2
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
2(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(2)
Completed(1)
Other(1)
Detailed Status
unknown1
Completed1
Not yet recruiting1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 22 (50.0%)
Phase 32 (50.0%)
Trials by Status
unknown125%
completed125%
not_yet_recruiting125%
recruiting125%
Recent Activity
1 active trials
Showing 4 of 4
recruitingphase_2
Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer
NCT05179889
not_yet_recruitingphase_3
Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM
NCT05948072
unknownphase_3
Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers
NCT02934464
completedphase_2
BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer
NCT00904839
Clinical Trials (4)
Showing 4 of 4 trials
NCT05179889Phase 2
Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer
NCT05948072Phase 3
Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM
NCT02934464Phase 3
Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers
NCT00904839Phase 2
BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4